The erythroblast transformation specific (ETS) gene fusion family is involved in the progression of a variety of cancers, and TMPRSS2:ERG is a prostate cancer-specific gene fusion; it has been noted that this gene fusion product interacts with PARP-1, and that olaparib was able to suppress ETS-positive (but not ETS-negative) prostate cancer cell invasion [37], yet no clinical data confirming this cellular effect is available. The gene discussed is TMPRSS2; the disease is prostate carcinoma.